ALK and non-small cell lung carcinoma: This therapeutic approach has now been extended to solid tumours, for example the targeting of ALK, ROS1, NTRK and RET fusion genes in non-small cell lung cancer (NSCLC) where the clinical impact has been far reaching with markedly improved survival outcomes [3, 4].